[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

624.P1.73 Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 4, 2010: 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies

Jasmine M. Zain, MD1, Francine M. Foss, MD2, Johann S. de Bono3*, Ameet Narwal1*, Ellen Neylon, NP, RN, BSN, OCN4*, George Blumenschein5*, U. Lassen, MD6*, Poul Knoblauch7*, Catherine S. Diefenbach, MD8 and Owen A. O'Connor, MD, PhD9

1Hematology/Oncology, NYU Langone Medical Center, New York, NY
2Yale Medical Oncology, New Haven, CT
3Institue of Cancer Resch/Royal Marsden, Sutton, Surrey, England
4New York University Cancer Institute, New York, NY
5University of Texas MD Anderson Cancer Center, Houston
6University Hospital Rigshospitalet, Copenhagen, Denmark
7TopoTarget, Copenhagen, Denmark
8New York University Cancer Institute, New York University Langone School of Medicine, New York, NY
9Department of Medicine, NYU Cancer Institute, NYU Langone Medical Canter, New York, NY

Poster Board Number: I-767
Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy

Gilles Andre Salles1, John Catalano, MBBS FRACP FRCPA2, Pierre Feugier, MD, PhD3*, Fritz C Offner, MD, PhD4, Reda Bouabdallah, MD5*, Dolores Caballero, MD6*, Pauline Brice, MD7*, Lars Moller Pedersen, MD8*, Corinne Haioun, MD, PhD9, David Belada, MD10*, Alain Delmer, MD11, David Simpson, FRACP, FRCPA, MB, CHB12, Herve Tilly, MD13, Sirpa Leppa14, Pierre Soubeyran, MD15*, Anton Hagenbeek, MD, PhD16, Olivier Casasnovas, MD17*, Tanin Intragumtornchai, MD, MSc18, Christophe Fermé19*, Maria Gomes da Silva20*, Catherine Sebban, MD21*, Andrew Lister, MD22*, Jane A Estell, MBBS, FRCPA, FRACP23, Gustavo Milone, MD24, Anne Sonet, MD25*, Armando Lopez-Guillermo, MD26, John Francis Seymour, MBBS, FRACP, Ph, D27* and Luc Xerri, MD5*

1Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
2 Haematology/Oncology, Peninsula Private Hospital , Frankston, Australia
3Service d'Hématologie, Hôpital Adultes de Brabois, Vandoeuvre Les Nancy, France
4Dienst Hematologie, University Hospital Ghent, Gent, Belgium
5Institut Paoli Calmettes, Marseille, France
6Hospital Clínico U. de Salamanca, Salamanca, Spain
7Hôpital Saint-Louis, AP-HP, Paris, France
8Odense University Hospital, Odense, Denmark
9Hematology, Hôpital Henri Mondor, Créteil, France
10Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic
11CHU de Reims Hematology, Hopital Robert Debre, Reims, France
12North Shore Hospital, Auckland, New Zealand
13Centre Henri Becquerel, Rouen, France
14Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
15Institut Bergonié,, Bordeaux, France
16University of Amsterdam Hematology, F4-224, Academic Medical Center, Amsterdam, Netherlands
17Hematology, CHU de Dijon, Dijon, France
18Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
19Institut Gustave Roussy, Villejuif, France
20Portuguese Institute of Oncology, Lisbon, Portugal
21Hematology, Centre Léon Bérard, Lyon, France
22Center for Medical Oncology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
23Dept. of Haematology, Concord Hosp., Concord, Australia
24Fundaleu Hospital, Buenos Aires, Argentina
25Université Catholique de Louvain, Montgodinne, Belgium
26Hematology, Hospital Clinic, Barcelona, Spain
27Peter MacCallum Cancer Centre St. Andrew's Place, East Melbourne, Australia

Poster Board Number: I-768
Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

Jonathan R Fromm, MD, PhD1, Julie A. McEarchern, PhD2*, Dana Kennedy, PharmD3*, Thomas Anju1*, Andrei R Shustov, MD4* and Ajay K Gopal, MD5

1Laboratory Medicine, University of Washington, Seattle, WA
2Experimental Therapeutics, Seattle Genetics, Inc., Bothell, WA
3Clinical Affairs, Seattle Genetics, Inc., Bothell, WA
4Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
5Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

Poster Board Number: I-769
Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study

Ho-Young Yhim1*, Jae-Yong Kwak1, Hye Jin Kang2*, Seok Jin Kim, MD, PhD3, Won Seog Kim4*, Jin Seok Kim5*, Chul Won Choi6*, Hyeon Seok Eom7*, Jeong-A Kim8, Jae Hoon Lee, MD9, Jong Ho Won10*, Hyeok Shim, MD11*, Dae Ho Lee12* and Cheolwon Suh, MD13

1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea
2Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, South Korea
3Medicine, Samsung Med. Ctr., Seoul, South Korea
4Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea
5Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, South Korea
6Internal Medicine, Korea University Medical Center, Guro Hospital, Seoul, South Korea
7Hematology-Oncology Clinic, National Cancer Center, Goyang, South Korea
8Department of Internal Medicine, The College of Medicine, The Catholic University of Korea, Seoul, South Korea
9Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science, Incheon, South Korea
10Internal medicine, Soonchunhyang University Hospital, Seoul, South Korea
11Internal Medicine, Wonkwang University School of Medicine, Iksan, South Korea
12Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
13Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Poster Board Number: I-770
The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study

Seok Jin Kim, MD, PhD1, Hyeon-Seok Eom2*, Jin Seok Kim3*, Hye Jin Kang4*, Hyo Jung Kim, MD, PhD5*, Sung-Kyu Park6*, Jooryung Huh7*, Young Hyeh Ko, MD8*, Cheolwon Suh, MD9 and Won Seog Kim10*

1Medicine, Samsung Med. Ctr., Seoul, South Korea
2Hematology–Oncology Clinic, National Cancer Center
3Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, South Korea
4Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, South Korea
5Hematology-Oncology, Hallym University College of Medicine, Anyangsi, South Korea
6Internal Medicine, Soonchunhyang University College of Medicine
7Pathology, Asan Medical Center
8Samsung Medical Center, Souel, South Korea
9Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
10Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea

Poster Board Number: I-771
Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL

Kevin Doner, MD1*, Ian W. Flinn, MD, PhD2, Brian K. Ulrich, MD3*, Stephen J. Noga, MD, PhD4, Naveed M. Chowhan, MD5*, Steven W. Papish, MD6*, Tallat Mahmood, MD7*, James A Reeves, MD8*, Nicholas J. Di Bella, MD9, Gerald J. Robbins, MD10*, Radhakrishnan Ramchandren11, Sein Aung12, William Lawler, MD13, Sudha Parasuraman, MD14, Maria M. Corvez, BA14*, George Mulligan, PhD15* and John P. Leonard, MD16

1Hematology/Oncology, Texas Oncology P.A., Austin, TX
2Oncology, Sarah Cannon Research Institute, Nashville, TN
3Texas Oncology, Texoma Cancer Center, Wichita Falls, TX
4Medical Oncology and Hematology, Sinai Hospital of Baltimore, Baltimore, MD
5Hematology/Oncology, Cancer Care Center, New Albany, IN
6Hematology-Oncology Associates of Northern New Jersey, Morristown, NJ
7Hematology/Oncology, Mid-Michigan Physicians, Lansing, MI
8Hematology/Oncology, Florida Cancer Specialists, Fort Myers, FL
9US Oncology, Aurora, CO
10Medical Oncology-Hematology, Florida Cancer Institute, New Port Richey, FL
11Hematology-Oncology, Karmanos Cancer Institute, Detroit, MI
12Harry Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, MD
13Hematology/Oncology, St Jude Heritage Healthcare, Fullerton, CA
14Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA
15Molecular Medicine, Millennium Pharmaceuticals, Inc., Cambridge, MA
16Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY

Poster Board Number: I-772
Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin Jr., MD1, Maria Alma Rodriguez, MD2, Ariela Noy, MD3, Carol S. Portlock, MD3, David Straus, MD3*, Peter McLaughlin, MD2*, Barbara Pro, MD4*, Luis Fayad, MD2*, F.B. Hagemeister, MD5, Brett Wegner6*, Otilia Dumitrescu, MD7*, Neetha Pandit Tasker, MD8*, Craig H Moskowitz, MD9 and Andrew D Zelenetz, MD, PhD3

1Hematologic Oncology - Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York City, NY
2Lymphoma & Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
3Hematologic Oncology - Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY
4Fox Chase Cancer Center, Philadelphia, PA
5Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
6Memorial Sloan-Kettering Cancer Center, New York, NY
7Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY
8Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
9Hematologic-Oncology - Lymphoma & Hematology Services, Memorial Sloan Kettering Cancer Center, New York, NY

Poster Board Number: I-773
Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program

Stéphanie Harel1*, Emmanuel Bachy2*, Corinne Haioun, MD, PhD3, Emmanuel Gyan, MD, PhD4*, Gandhi Damaj, MD5, Nadine Morineau, MD6*, Bertrand Arnulf7*, Olivier Hermine, MD, PhD8* and Richard Delarue, MD1*

1Hematology, Necker Hospital, Paris, France
2Hematology, Lyon Sud Hospital, Lyon, France
3Hematology, Hôpital Henri Mondor, Créteil, France
4CHRU de Tours, Service d'hématologie et thérapie cellulaire, Tours, France
5Hematology, University Hospital-CHU Sud, Amiens, France
6Hématologie, Centre Catherine de Sienne, Nantes
7Saint Louis, Paris, France
8Necker Hospital, Paris, France

Poster Board Number: I-774
A Phase II Trial of Ofatumumab In Subjects with Waldenstrom’s Macroglobulinemia

Richard R. Furman, MD1, Herbert Eradat, MD, MS2, Julie C. Switzky, RN, MSN, MBA3*, Suzanne R Hayman, MD4, Craig C. Hofmeister, MD5, Nathalie A. Avignon, BA6*, John P. Leonard, MD7, Morton Coleman, MD8*, Qiming Liao, PhD9*, Damini N. Shah10*, Stephanie Brownell-Buttich, BFA10*, Steen Lisby, MD, DMSC11* and Thomas S. Lin, MD, PhD10

1Weill Cornell Medical College, New York, NY
2David Geffen School of Medicine, Los Angeles, CA
3Oncology, GlaxoSmithKline, Collegeville, PA
4Division of Hematology, Mayo Clinic, Rochester, MN
5Internal Medicine, Division of Hematology, The Ohio State University Medical Center, Columbus, OH
6Weill Cornell Medical College, New York
7Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY
8Medicine, Divison of Hematology and Oncology, Weill Cornell Medical College, New York, NY
9GlaxoSmithKline, Research Triangle Park, NC
10GlaxoSmithKline, Collegeville, PA
11Genmab A/S, Copenhagen K, Denmark

Poster Board Number: I-775
Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies

Kunihiro Tsukasaki, MD, PhD1*, Michinori Ogura, MD, PhD2, Hirokazu Nagai, MD, PhD3, Jun Taguchi, MD, PhD1*, Tatsuya Suzuki, MD, PhD2*, Dai Maruyama, MD, PhD4*, Uchida Toshiki, MD, PhD2*, Takashi Oyama, MD, PhD2*, Tomomitsu Hotta, MD, PhD5 and Kensei Tobinai, MD, PhD4

1Department of Molecular Medicine and Hematology, Molecular Medicine Unit,Atomic Bomb Disease Institute, Nagasaki Univ, Nagasaki, Japan
2Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
3Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
4Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
5National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Poster Board Number: I-776
Pooled Analysis of Aids-Malignancy Consortium (AMC) Trials Evaluating Rituximab Plus Either CHOP or Infusional EPOCH Chemotherapy In HIV-Associated Non-Hodgkin’s Lymphoma

Stefan K Barta, MD, MS, MRCP1, Jeannette Y Lee, Ph.D.2*, Joseph A Sparano, MD3*, Lawrence D Kaplan, MD4 and Ariela Noy, MD5

1Department of Oncology, Albert-Einstein Cancer Center - Montefiore Medical Center, Bronx, NY
2Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
3Albert-Einstein Cancer Center - Montefiore Medical Center, Bronx, NY
4Hematology/Oncology, University of California, San Francisco, CA
5Memorial Sloan-Kettering Cancer Ctr., New York, NY

Poster Board Number: I-777
Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update

Liat Vidal, MD1*, Anat Gafter-Gvili, MD1*, Gilles Salles2, Martin H. Dreyling, PhD3, Michele Ghielmini, MD4, Shu-Fang Hsu Schmitz5*, Ruth Pettengell, FRACP, PhD6*, Mathias Witzens-Harig7* and Ofer Shpilberg, MD, MPH8*

1Institute of Hematology, Rabin Medical Center, Petah-Tikva and Sackler School of Medicine, Tel Aviv University, Israel
2Hematologie, Centre Hopitalier Universitaire Lyon-Sud, Pierre-Benite, France
3Department of Internal Medicine III, University Hospital Munich, Munich, Germany
4Medical Oncology, Oncology Inst. of Southern Switzerland, Bellinzona, Switzerland
5Medical Oncology, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
6Haematology, St George's University of London, London, United Kingdom
7University Hospital of Heidelberg, Heidelberg, Germany
8Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel

Poster Board Number: I-778
Prognostic Significance of Interim 18f-FDG PET/CT for the Treatment of Diffuse Large B-Cell Lymphoma In the Post-Rituximab Era

Deok-Hwan Yang1, Jung-Joon Min2*, Ho-Chun Song2*, Yong Yeon Jeong3*, Woong-Ki Chung4*, Soo-Young Bae5*, Jae-Sook Ahn5*, Yeo-Kyeoung Kim, MD, PhD6*, Hee-Seung Bom7*, Ik-Joo Chung5*, Hyeoung Joon Kim8 and Je-Jung Lee1*

1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea
2Nuclear medicine, Chonnam National University Hwasun Hospital, Jeollanam-do
3Radiology, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
4Radiation oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
5Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
6Hematology/Oncology, Chonnam National Univ. Hwasun Hospital, Hwasun, South Korea
7Nuclear medicine, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
8Genome Research Center for Hematopoietic Diseases, Chonnam National Univ. Hwasun Hospital, Hwasun, South Korea

Poster Board Number: I-779
Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era

Miyuki Hayama1*, Masataka Okamoto, MD, PhD2*, Yuki Hagiwara1*, Ken Tanae1*, Mika Kohri1*, Naoki Takahashi1*, Tadashi Yoshino2*, Koichi Ohshima2* and Nozomi Niitsu, MD1

1Department of Hematology, International Medical Ctr., Saitama Medical Univ., Hidaka, Japan
2adult Lymphoma Treatment Study Group (ALTSG), Nagoya, Japan

Poster Board Number: I-780
Phase II Study of Velcade® Plus Mabthera®  In Relapsed Follicular Lymphomas

Stefano Sacchi1, Raffaella Marcheselli, MS2*, Alessia Bari, MD3*, Eliana Valentina Liardo, MD3*, Stefano Luminari, MD4*, Francesco Merli5*, Antonio Lazzaro6*, Santo Neri, MD7*, Angelo Michele Carella8, Alberto Fragasso9*, Simona Falorio10*, Gabriele Buda11*, Pellegrino Musto, MD12*, Matteo Dell'Olio, MD13* and Luca Baldini14*

1Oncologia ed Ematologia, Università  di Modena, Modena, Italy
2Program of Innovative Therapy in Oncology and Hematology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
3Oncologia ed Ematologia, Università di Modena, Modena, Italy
4Department of Onco-Hematology, Policlinico di Modena, Modena, Italy
5Arcispedale S. Maria Nuova, Reggio Emilia, Italy
6Ospedale di Piacenza, Piacenza, Italy
7UO Ematologia, A.O. Ospedali Riuniti Papardo Piemonte , Messina, Italy
8Ospedale San Martino Genova, Genova, Italy
9Ospedale di Matera, Matera, Italy
10Ospedale di Pescara, Pescara, Italy
11Università di Pisa, Pisa, Italy
12Onco-Hematology, Department of Hematology, Scientific Institute of Research and Cure, Reference Cancer Center of Basilicata, Rionero in Vulture,, Rionero in Vulture (Pz), Italy
13Hematology, IRCCS - Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy
14IRCCS Policlinico, Università di Milano, Milano, Italy

Poster Board Number: I-781
Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD1, Simona Bassi2*, Felicitas Hitz3*, Walter Mingrone4*, Thomas Pabst5, Lidija Cevreska, MD, PhD6, Auro del Giglio, MD7, Daniel A. Vorobiof8*, Mathew Simcock9* and Michele Ghielmini, MD10*

1Internal Medicine, Kantonsspital, Munsterlingen, Switzerland
2Istituto Europeo di Oncologia, Milano, Italy
3Medical Oncology, Kantonsspital St.Gallen, St.Gallen, Switzerland
4KantonsSpital Olten, Olten, Switzerland
5Institute of Medical Oncology, University Hospital, Bern, Switzerland
6University Clinic of Hematology-Skopje, Skopje, Macedonia
7Hematology and Oncology, ABC Fondation School of Medicine, Sao Paulo, Brazil
8Sandton Oncology Center, Johannesburg, South Africa
9Swiss Group for Clincal Cancer Research, Coordinating Center, Bern, Switzerland
10Medical Oncology, Oncology Inst. of Southern Switzerland, Bellinzona, Switzerland

Poster Board Number: I-782
Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

Alden A. Moccia1*, Paul Hoskins1*, Richard Klasa1, Kerry J. Savage1, Tamara Shenkier1*, Graham W. Slack2*, Randy D. Gascoyne2, Joseph M. Connors1 and Laurie H. Sehn1

1Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
2Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada

Poster Board Number: I-783
A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response

Arne Kolstad, MD, PhD1*, Shraddha Kumari, PhD2*, Gunnar Kvalheim, MD, PhD1, Trond Velde Bogsrud, MD, PhD3*, Ulf Madsbu, MD4*, Trond Hagtvedt, MD4*, Gustav Gaudernack, MD2*, Grethe Lauvvang, RN1*, Harald Holte, MD, PhD1* and Johanna Olweus, MD, PhD2*

1Dept of Oncology, Norwegian Radium Hospital, Oslo, Norway
2Dept of Immunology, Norwegian Radium Hospital, Oslo, Norway
3Dept of Nuclear Medicine, Norwegian Radium Hospital, Oslo, Norway
4Dept of Radiology, Norwegian Radium Hospital, Oslo, Norway

Poster Board Number: I-784
Low Absolute Lymphocyte Count and Addition of Rituximab Confer High Risk for Interstitial Pneumonia In Patients with Diffuse Large B Cell Lymphoma

Yuan-Bin Yu, MD1*, Yu-Chung Huang, MD2*, Chia-Jen Liu3*, Jih-tung Pai3*, Hsueh-Ju Lu4*, Chun-Yu Liu5*, Ying-Chung Hong, MD6*, Liang-Tsai Hsiao, MD4, Jyh-Pyng Gau, MD4*, Hui-Chi Hsu, MD7*, Tzeon-Jye Chiou6*, Jin-Hwang Liu, MD, PhD6 and Cheng-Hwai Tzeng, MD5

1Hematology and Oncology, Taipei Veterans General Hosp., Taipei, Taiwan
2Hematology-Oncology, Taipei Veterans General Hospital, Taiwan, Taiwan
3Hematology & Oncology, Taipei Veterans General Hospital, Taiwan, Taiwan
4Hematology & Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
5National Yang-Ming Univ. Section of Hem-Onco; Dept. of Medicine, Veterans General Hospital, Taipei, Taiwan
6Taipei Veterans General Hospital, Taipei, Taiwan
7General Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Poster Board Number: I-785

*signifies non-member of ASH